Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

BACKGROUND: Small cell lung cancer (SCLC) constitutes 15% of all lung cancer cases, with a comparatively low survival rate. The advent of immune checkpoint inhibitors (ICIs) has provided new alternatives for treating SCLC. However, the effectiveness of camrelizumab in the treatment of SCLC remains u...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Jizheng, Sui, Lili, Wang, Hong, Chen, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352824/
https://www.ncbi.nlm.nih.gov/pubmed/37469402
http://dx.doi.org/10.3389/fonc.2023.1180735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352824/
https://www.ncbi.nlm.nih.gov/pubmed/37469402
http://dx.doi.org/10.3389/fonc.2023.1180735

Ejemplares similares